Previous 10 | Next 10 |
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU) - CHMP positive opinion is based on data from two Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2[1],[2] - If approved, th...
Whether you're a retiree looking to help pay your bills or you just want to save up for your next vacation, everyone can use some extra cash every month. And one way you can generate more money for your portfolio is by investing in dividend stocks. Few dividend stocks pay on a monthly basis...
Inflation continues to come in above expectations and continues to run well ahead of the 2% target range. More and more investors and market watchers come to the conclusion that inflation may not be that transitory after all. Prepare your portfolio accordingly - there are viable m...
Inflation concerns have started to affect market sentiment but it is highly uncertain if that will lead to a real market correction or just some short-term dips. I am continuing my monthly investment plans while still awaiting a market correction or possibly a real crash once market e...
After the recent FDA black box warning of JAKi, Arena Pharmaceuticals' share price has rallied recovering some of its 2021 losses. In this article, Etrasimod's ulcerative colitis phase 2 data will be analyzed and explain what our views for the S1P-R class moving forward. Arena Pha...
With the market 22% historically overvalued, many of the world's best blue-chips are trading at unattractive levels. In fact, Bank of America thinks stocks will barely deliver positive returns over the next decade. Fortunately, it's always a market of stocks, not a stock market an...
AbbVie is answering the bell by building a stronger diversified portfolio for the post-Humira stage. Humira has long been the TOP selling drug in the world. Management has grown an already strong dividend yield that is well covered by strong cash flows. For further details s...
My last article on AbbVie Inc. (ABBV) examined its wide moat, high return on capital employed, and superb scalability. This article examines the stock with a focus on its growth sustainability and capital allocation effectiveness like Buffett – as a long-term business owner. ...
4 Trending Biotech Stocks To Watch Amid AstraZeneca’s News While investors eagerly await the beginning of the third-quarter earnings season, biotech stocks continue to gain traction. For the most part, this area of the stock market today has plenty to offer investors now....
Ahead of the launch of its first product, ChemoCentryx (NASDAQ:CCXI) has bolstered its executive team with the appointment of Rita I. Jain as the company’s new chief medical officer. Dr. Jain a board-certified rheumatologist with over 20 years of experience in drug development, will al...
News, Short Squeeze, Breakout and More Instantly...
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.32% on an annualized basis producing an average annual return of 11.69%....
2024-04-30 09:59:20 ET The stock market is where investors trade shares of publicly traded companies. Among various investment options, dividend stocks are popular for their potential to provide income through regular dividend payments. These stocks are often shares of well-established ...
2024-04-29 11:00:06 ET Evan Seigerman from BMO Capital issued a price target of $180.00 for ABBV on 2024-04-29 09:49:00. The adjusted price target was set to $180.00. At the time of the announcement, ABBV was trading at $158.5841. The overall price target consensus is at...